Antidepressant Market in the US 2015-2019: Key Vendors are Actavis, Eli Lilly, GSK, Otsuka Pharmaceutical and Pfizer
Research and Markets has announced the addition of the "Antidepressant Market in the US 2015-2019" report to their offering.
Increased awareness of depression among the medical community, patients, and the families of patients is one major trend in this market. This can result in an increase in the number of treatment-seeking patients, which, in turn, can result in an increase in the overall consumption of medicines.
According to the report, an increase in patient population and changes in lifestyles are major factors propelling the growth of the market. Current treatment options do not provide a cure for the disorder, hence, there is a significant unmet need in the market. Therefore, drugs that can cause remission of depression in patients are expected to drive the growth of the market.
Further, the report states that one of the major challenges in the market is the expiry of the patents of major branded drugs, which is expected to lead to the erosion of their market share and a fall in the revenue generated by them. This is also expected to impact the size of the Antidepressant market in the US.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Product Profiles
05. Market Research Methodology
06. Introduction
07. Disorder Overview
08. Market Landscape
09. Market Segmentation by Mechanism of Action
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
18. Key Vendor Analysis
19. Other Reports in this Series
Companies Mentioned:
Abbott Laboratories
Actavis
AstraZeneca
Aurobindo Pharma
Bristol-Myers Squibb
Dr. Reddy's Laboratories
Eli Lilly and Company
GlaxoSmithKline
H. Lundbeck
Janssen Pharmaceuticals
Lupin
Novartis
Otsuka Pharmaceutical
Pfizer
Pierre Fabre
Shire
Somerset Pharmaceuticals
Sun Pharmaceutical
Sunovion Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical
Torrent Pharmaceuticals
Valeant Pharmaceuticals
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.